0001209191-21-033362.txt : 20210517
0001209191-21-033362.hdr.sgml : 20210517
20210517215701
ACCESSION NUMBER: 0001209191-21-033362
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210515
FILED AS OF DATE: 20210517
DATE AS OF CHANGE: 20210517
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Chowdhury Badrul A.
CENTRAL INDEX KEY: 0001776662
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-32157
FILM NUMBER: 21933587
MAIL ADDRESS:
STREET 1: PROTEOSTASIS THERAPEUTICS, INC.
STREET 2: 80 GUEST STREET, SUITE 500
CITY: BOSTON
STATE: MA
ZIP: 02135
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Savara Inc
CENTRAL INDEX KEY: 0001160308
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 841318182
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 900 S. CAPITAL OF TEXAS HIGHWAY
STREET 2: SUITE 150
CITY: AUSTIN
STATE: TX
ZIP: 78746
BUSINESS PHONE: 512-614-1848
MAIL ADDRESS:
STREET 1: 900 S. CAPITAL OF TEXAS HIGHWAY
STREET 2: SUITE 150
CITY: AUSTIN
STATE: TX
ZIP: 78746
FORMER COMPANY:
FORMER CONFORMED NAME: Mast Therapeutics, Inc.
DATE OF NAME CHANGE: 20130312
FORMER COMPANY:
FORMER CONFORMED NAME: ADVENTRX PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20030613
FORMER COMPANY:
FORMER CONFORMED NAME: BIOKEYS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20010928
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-05-15
0
0001160308
Savara Inc
SVRA
0001776662
Chowdhury Badrul A.
6836 BEE CAVE ROAD
BUILDING III, SUITE 200
AUSTIN
TX
78746
0
1
0
0
CHIEF MEDICAL OFFICER
Common Stock
2021-05-15
4
M
0
200000
0.00
A
200000
D
Common Stock
2021-05-17
4
S
0
50000
1.5574
D
150000
D
Restricted Stock Units
0.00
2021-05-15
4
M
0
200000
0.00
D
Common Stock
200000
0
D
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2020 in order to satisfy tax withholding obligations in connection with the vesting of restricted stock units on May 15, 2021.
The price is a weighted average sale price. The sale prices ranged from $1.50 to $1.61. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
The restricted stock units vested in full on May 15, 2021.
/s/ David Lowrance as attorney-in-fact for Badrul Chowdhury
2021-05-17